Professor, Medicine-Rheumatology and Pathology

MEMPHIS TN 381040000
Tel: (901) 577-7281


  • Ph.D., Wayne State University, Immunology
  • M.S., Michigan Statue University, Immunology
  • B.S., Michigan State University, Medical Technology

My Current CV

Research Keywords

 Immunology, autoimmunity, HLA, rheumatoid arthritis, T cells

Research Interest/Specialty

    Dr. Rosloniec’s major research interests are focused on deciphering the role of MHC class II molecules in conferring susceptibility to autoimmune diseases, and the development of novel therapies by which autoantigen specific T cells can be regulated.  His principal area of emphasis is the disease rheumatoid arthritis (RA), and the immunopathogenesis that confers susceptibility to this disease.  RA is a chronic and crippling autoimmune disease that affects 1 to 2% of the total population.  It is one of many autoimmune diseases that are only treatable by regimens that adversely affect the entire immune system, and in some instances other organ systems as well.  A more complete understanding of the function that HLA genetic factors play in controlling susceptibility to RA can lead to the development of new, immuno-specific therapies that will greatly reduce the health care problems associated with current non-specific therapies.  Toward these goals, Dr. Rosloniec’s current research is focused on:  1) defining the functional relationship between MHC class II molecules and how these structures stimulate T cells and mediate susceptibility to autoimmune diseases; 2) determining the role of Th1 responses to post-translationally modified proteins in the susceptibility to autoimmunity; and 3) developing an antigen specific therapy for regulating the autoimmune T cells using genetically engineered cells.



  1. Brand, DD, Latham, KA, Rosloniec, EF. Collagen-induced arthritis. Nat Protoc, 2 (5), 1269-75, 2007.
  2. Rosloniec, EF, Brandstetter, T, Leyer, S, Schwaiger, FW, Nagy, ZA. Second-generation peptidomimetic inhibitors of antigen presentation effectively treat autoimmune diseases in HLA-DR-transgenic mouse models. J Autoimmun, 27 (3), 182-95, 2006.
  3. Rosloniec, EF, Ivey, RA, Whittington, KB, Kang, AH, Park, HW. Crystallographic structure of a rheumatoid arthritis MHC susceptibility allele, HLA-DR1 (DRB1*0101), complexed with the immunodominant determinant of human type II collagen. J Immunol, 177 (6), 3884-92, 2006.
  4. Sakurai, Y, Brand, DD, Tang, B, Rosloniec, EF, Stuart, JM, Kang, AH, Myers, LK. Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice. Arthritis Res Ther, 8 (5), R150, 2006.
  5. Sakurai, Y, Tang, B, Rosloniec, EF, Stuart, JM, Kang, AH, Myers, LK. Molecular characterization of an arthritogenic collagen peptide interacting with I-Ar. Immunology, 117 (1), 136-42, 2006.
  6. Latham, KA, Whittington, KB, Zhou, R, Qian, Z, Rosloniec, EF. Ex vivo characterization of the autoimmune T cell response in the HLA-DR1 mouse model of collagen-induced arthritis reveals long-term activation of type II collagen-specific cells and their presence in arthritic joints. J Immunol, 174 (7), 3978-85, 2005.
  7. Myers, LK, Tang, B, Brand, DD, Rosloniec, EF, Stuart, JM, Kang, AH. Efficacy of modified recombinant type II collagen in modulating autoimmune arthritis. Arthritis Rheum, 50 (9), 3004-11, 2004.
  8. Brand, DD, Kang, AH, Rosloniec, EF. The mouse model of collagen-induced arthritis. Methods Mol Med, 102, 295-312, 2004.
  9. Cremer, MA, Ye, XJ, Myers, LK, Brand, DD, Rosloniec, EF, Kang, AH. T cell immunity to type II collagen in the biobreeding rat: the identification and characterization of RT1u-restricted T cell epitopes on alpha 1(II). J Immunol, 173 (3), 1795-801, 2004.
  10. He, X, Rosloniec, EF, Myers, LK, McColgan, WL, Gumanovskaya, M, Kang, AH, Stuart, JM. T cell receptors recognizing type II collagen in HLA-DR-transgenic mice characterized by highly restricted V beta usage. Arthritis Rheum, 50 (6), 1996-2004, 2004.
  11. Myers, LK, Sakurai, Y, Rosloniec, EF, Stuart, JM, Kang, AH. An analog peptide that suppresses collagen-induced arthritis. Am J Med Sci, 327 (4), 212-6, 2004.
  12. Rosloniec, EF, Whittington, KB, He, X, Stuart, JM, Kang, AH. Collagen-induced arthritis mediated by HLA-DR1 (*0101) and HLA-DR4 (*0401). Am J Med Sci, 327 (4), 169-79, 2004.
  13. Latham, KA, Zamora, A, Drought, H, Subramanian, S, Matejuk, A, Offner, H, Rosloniec, EF. Estradiol treatment redirects the isotype of the autoantibody response and prevents the development of autoimmune arthritis. J Immunol, 171 (11), 5820-7, 2003.
  14. Brand, DD, Kang, AH, Rosloniec, EF. Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol, 25 (1), 3-18, 2003.
  15. Myers, LK, Sakurai, Y, Tang, B, He, X, Rosloniec, EF, Stuart, JM, Kang, AH. Peptide-induced suppression of collagen-induced arthritis in HLA-DR1 transgenic mice. Arthritis Rheum, 46 (12), 3369-77, 2002.
  16. Rosloniec, EF, Latham, K, Guedez, YB. Paradoxical roles of IFN-gamma in models of Th1-mediated autoimmunity. Arthritis Res, 4 (6), 333-6, 2002.
  17. Brand, DD, Whittington, KB, Rosloniec, EF. I-Aq and I-Ap bind and present similar antigenic peptides despite differing in their ability to mediate susceptibility to autoimmune arthritis. Autoimmunity, 34 (2), 133-45, 2002.
  18. Brand, DD, Myers, LK, Whittington, KB, Latham, KA, Stuart, JM, Kang, AH, Rosloniec, EF. Detection of early changes in autoimmune T cell phenotype and function following intravenous administration of type II collagen in a TCR-transgenic model. J Immunol, 168 (1), 490-8, 2002.
  19. Rosloniec, EF, Whittington, KB, Zaller, DM, Kang, AH. HLA-DR1 (DRB1*0101) and DR4 (DRB1*0401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen. J Immunol, 168 (1), 253-9, 2002.
  20. Guedez, YB, Whittington, KB, Clayton, JL, Joosten, LA, van de Loo, FA, van den Berg, WB, Rosloniec, EF. Genetic ablation of interferon-gamma up-regulates interleukin-1beta expression and enables the elicitation of collagen-induced arthritis in a nonsusceptible mouse strain. Arthritis Rheum, 44 (10), 2413-24, 2001.
  21. Rosloniec, EF, Cremer, M, Kang, A, Myers, LK. Collagen-induced arthritis. Curr Protoc Immunol, Chapter 15, Unit 15.5, 2001.
  22. Myers, LK, Kang, AH, Postlethwaite, AE, Rosloniec, EF, Morham, SG, Shlopov, BV, Goorha, S, Ballou, LR. The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum, 43 (12), 2687-93, 2000.
  23. Gumanovskaya, ML, Myers, LK, Rosloniec, EF, Stuart, JM, Kang, AH. Intravenous tolerization with type II collagen induces interleukin-4-and interleukin-10-producing CD4+ T cells. Immunology, 97 (3), 466-73, 1999.
  24. Myers, LK, Brand, DD, Ye, XJ, Cremer, MA, Rosloniec, EF, Bodo, M, Myllyharju, J, Helaakoski, T, Nokelainen, M, Pihlajaniemi, T, Kivirikko, K, Yang, CL, Ala-Kokko, L, Prockop, DJ, Notbohm, H, Fietzek, P, Stuart, JM, Kang, AH. Characterization of recombinant type II collagen: arthritogenicity and tolerogenicity in DBA/1 mice. Immunology, 95 (4), 631-9, 1998.
  25. Myers, LK, Tang, B, Rosloniec, EF, Stuart, JM, Chiang, TM, Kang, AH. Characterization of a peptide analog of a determinant of type II collagen that suppresses collagen-induced arthritis. J Immunol, 161 (7), 3589-95, 1998.
  26. Tang, B, Myers, LK, Rosloniec, EF, Whittington, KB, Stuart, JM, Kang, AH. Characterization of signal transduction through the TCR-zeta chain following T cell stimulation with analogue peptides of type II collagen 260-267. J Immunol, 160 (7), 3135-42, 1998.
  27. Cremer, MA, Rosloniec, EF, Kang, AH. The cartilage collagens: a review of their structure, organization, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease. J Mol Med, 76 (3-4), 275-88, 1998.
  28. Kawamura, S, Miyahara, H, Esaki, Y, Myers, LK, Rosloniec, EF, Stuart, JM, Kang, AH. Restricted TCR V alpha repertoire in the T cell response to a tolerogenic determinant of type II collagen. J Immunol, 158 (12), 6013-8, 1997.
  29. Myers, LK, Rosloniec, EF, Cremer, MA, Kang, AH. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci, 61 (19), 1861-78, 1997.
  30. Brand, DD, Marion, TN, Myers, LK, Rosloniec, EF, Watson, WC, Stuart, JM, Kang, AH. Autoantibodies to murine type II collagen in collagen-induced arthritis: a comparison of susceptible and nonsusceptible strains. J Immunol, 157 (11), 5178-84, 1996.
  31. Rosloniec, EF, Whittington, KB, Brand, DD, Myers, LK, Stuart, JM. Identification of MHC class II and TCR binding residues in the type II collagen immunodominant determinant mediating collagen-induced arthritis. Cell Immunol, 172 (1), 21-8, 1996.
  32. Ballou, LR, Laulederkind, SJ, Rosloniec, EF, Raghow, R. Ceramide signalling and the immune response. Biochim Biophys Acta, 1301 (3), 273-87, 1996.
  33. Rosloniec, EF, Brand, DD, Whittington, KB, Stuart, JM, Ciubotaru, M, Ward, ES. Vaccination with a recombinant V alpha domain of a TCR prevents the development of collagen-induced arthritis. J Immunol, 155 (9), 4504-11, 1995.
  34. Miyahara, H, Myers, LK, Rosloniec, EF, Brand, DD, Seyer, JM, Stuart, JM, Kang, AH. Identification and characterization of a major tolerogenic T-cell epitope of type II collagen that suppresses arthritis in B10.RIII mice. Immunology, 86 (1), 110-5, 1995.
  35. Brand, DD, Myers, LK, Terato, K, Whittington, KB, Stuart, JM, Kang, AH, Rosloniec, EF. Characterization of the T cell determinants in the induction of autoimmune arthritis by bovine alpha 1(II)-CB11 in H-2q mice. J Immunol, 152 (6), 3088-97, 1994.
  36. Myers, LK, Rosloniec, EF, Seyer, JM, Stuart, JM, Kang, AH. A synthetic peptide analogue of a determinant of type II collagen prevents the onset of collagen-induced arthritis. J Immunol, 150 (10), 4652-8, 1993.